incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-15. Numbers and descriptions here follow the published literature rather than marketing material.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
To achieve the antibacterial effect on the staphylococci cultures that Fleming observed, the mould had to be producing sufficient amounts of penicillin no later than when the bacterial growth was beginning to form visible colonies, because penicillin is only effective on bacteria when they are reproducing. Fortuitously, the temperature in the laboratory during that August was optimum first for the growth of the mould, below 20 °C, and later in the month for the bacteria, when it reached 25 °C. Fleming was a bacteriologist, not a chemist, so he left most of the chemical work to Craddock. In January 1929, Fleming recruited Frederick Ridley, a former research student of his with a background in biochemistry, to examine the chemical properties of the mould. Craddock and Ridley could not isolate penicillin, and before the experiments were over, both had left for other jobs. Fleming reported his findings to the British Journal of Experimental Pathology on 10 May 1929, and they were published in the next month's issue, but the article failed to attract much attention. Fleming was quite unsure of the medical application of his work and was more concerned with its application for bacterial isolation. The article also contained serious errors. Although Ridley and Craddock had demonstrated that penicillin was soluble in ether, acetone and alcohol as well as in water – information that would be critical to its isolation – Fleming erroneously claimed that it was soluble in alcohol and insoluble in ether and chloroform, which had not been tested.
== Geography == According to the United States Census Bureau, the city has an area of 2.70 square miles (6.99 km2); 2.67 square miles (6.92 km2) is land and 0.03 square miles (0.08 km2) is water. The Sauk River bisects Cold Spring from the southwest. Cold Spring is in Wakefield Township geographically but is a separate entity.
Although a crystal structure of catechol oxidase has been solved, questions concerning the exact mechanism of the reaction remain. One mechanism proposed by Eicken et al. is based on the crystal structure of catechol oxidase purified from Ipomoea batatas. The catalytic cycle begins with the catechol oxidase in its native oxidized Cu(II)-Cu(II) state with a coordinated hydroxide ion bridging the two copper centers. As catechol enters the active site, a proton is abstracted from one of the alcohols. The catechol coordinates with a Cu(II) center in a monodentate fashion, displacing one of the coordinating histidine residues. The coordinated hydroxide ion abstracts another proton from catechol to form water, and the catechol is oxidized to o-quinone. The two resulting electrons reduce both copper centers to their Cu(I)-Cu(I) state. Dioxygen then binds one copper center, displacing the coordinated water molecule, and another molecule of catechol binds to the other copper center, displacing another histidine residue. This forms a complex in which one copper center has a tetragonal planar coordination with His240, His244 and the dioxygen molecule. The other copper center retains its initial tetragonal pyramidal geometry with dioxygen, His88 and His118 in the equatorial positions, and His109 in an axial position. In this state, the enzyme active site is in a ternary catechol oxidase–O22−–catechol complex. Two electrons are transferred from the substrate to the dioxygen, followed by cleavage of the O–O bond.
=== Uniformity requirements === The chemical processing and synthesis of high-performance technological components for the private, industrial, and military sectors requires the use of high-purity ceramics (oxide ceramics, such as aluminium oxide or copper(II) oxide), polymers, glass-ceramics, and composite materials, as metal carbides (SiC), nitrides (Aluminum nitrides, Silicon nitride), metals (Al, Cu), non-metals (graphite, carbon nanotubes), and layered (Al + aluminium carbonate, Cu + C). In condensed bodies formed from fine powders, the irregular particle sizes and shapes in a typical powder often lead to non-uniform packing morphologies that result in packing density variations in the powder compact. Uncontrolled agglomeration of powders due to attractive van der Waals forces can also give rise to microstructural heterogeneity. Differential stresses that develop as a result of non-uniform drying shrinkage are directly related to the rate at which the solvent can be removed, and thus highly dependent upon the distribution of porosity. Such stresses have been associated with a plastic-to-brittle transition in consolidated bodies, and can yield to crack propagation in the unfired body if not relieved. In addition, any fluctuations in packing density in the compact as it is prepared for the kiln are often amplified during the sintering process, yielding inhomogeneous densification. Some pores and other structural defects associated with density variations have been shown to play a detrimental role in the sintering process by growing and thus limiting end-point densities.
== Organizations == Many countries are obligated by various international instruments and standards, such as the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, the 2000 Convention against Transnational Organized Crime, the 2003 United Nations Convention against Corruption, and the recommendations of the 1989 Financial Action Task Force on Money Laundering (FATF) to enact and enforce money laundering laws in an effort to stop narcotics trafficking, international organized crime, and corruption. Mexico, which has faced a significant increase in violent crime, established anti–money laundering controls in 2013 to curb the underlying crime issue. Formed in 1989 by the G7 countries, the Financial Action Task Force on Money Laundering (FATF) is an intergovernmental body whose purpose is to develop and promote an international response to combat money laundering. The FATF Secretariat is housed at the headquarters of the OECD in Paris. In October 2001, FATF expanded its mission to include combating the financing of terrorism. FATF is a policy-making body that brings together legal, financial, and law enforcement experts to achieve national legislation and regulatory AML and CFT reforms. As of 2014 its membership consists of 36 countries and territories and two regional organizations. FATF works in collaboration with a number of international bodies and organizations. These entities have observer status with FATF, which does not entitle them to vote, but permits them full participation in plenary sessions and working groups.
Sources: en.wikipedia.org
1 At the state elections on 15 February 1936, James Kenneally lost his East Perth seat to an Independent Labor candidate, Thomas Hughes. Kenneally and another candidate contested the poll citing Hughes's status as an undischarged bankrupt at the time of the poll (meaning that he was not eligible to stand), and a fresh by-election was called for 9 May, which Hughes won. On 13 May, Kenneally resigned from the Collier Ministry. Bert Hawke replaced him in the Executive Council and in two of his portfolios, whilst Millington and Wise reshuffled portfolios, in part to unite Works and Water Supplies under one minister. 2 Willcock assumed all of Collier's portfolios from 20 August 1936 until 27 August 1936 whilst Caucus selected a new Cabinet.
Lorcaserin, marketed under the brand name Belviq, was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating the 5-HT2C serotonin receptor in the hypothalamus, a region of the brain which is known to control appetite. It was approved in 2012, and in 2020 was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.
== Bismuth-213 == Bismuth-213 (213Bi) has a half-life of 45.6 minutes and decays mainly by beta emission to polonium-213; with only 2.1% going via alpha emission to thallium-209; however, as the polonium instantly decays by alpha, one alpha particle is emitted per atom. The amounts needed for medical use are always produced through its decay chain (the neptunium series) from either thorium-229 (limited supply due to the long life of that isotope) or actinium-225, which can be produced directly from radium-226, for example by bombardment with bremsstrahlung photons from a linear particle accelerator, knocking out a neutron and through beta decay giving actinium-225. In 1997, an antibody conjugate with 213Bi was used to treat patients with leukemia, and this isotope has otherwise been used in targeted alpha therapy (TAT) to treat a variety of cancers. Bismuth-213 is also produced in the decay of uranium-233, the fuel bred by thorium reactors, but as mentioned this goes through the long-lived thorium-229, so the production rates from each reactor will not be large.
== Mechanism of action == Dulaglutide binds to glucagon-like peptide 1 receptors, slowing gastric emptying and increasing insulin secretion by pancreatic Beta cells. Simultaneously the compound reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas, as glucagon is known to be inappropriately elevated in diabetic patients. GLP-1 is normally secreted by L cells of the gastrointestinal mucosa in response to a meal.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.